Skip to main content

Search

Reset all filters
60 Result(s)
Sort by

Pradaxa®

Pradaxa®

Prevention of strokes and blood clots in patients with abnormal heart rhythm (atrial fibrillation). Primary prevention of venous thrombo-embolic events (VTE) in adults after elective total hip or knee replacement surgery. Treatment of deep vein throm
Access to Healthcare Strategy Innovation

Access to Healthcare Strategy Innovation

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Hypertension

Hypertension

Click here for more information on Hypertension
Reimagining digital healthcare worldwide

Reimagining digital healthcare worldwide

How does our digital lab BI X innovate in Ingelheim and Shanghai? Read about success stories based on different ideation processes
Patient voices Ulrichs story

Patient voices Ulrichs story

Ulrich’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Patient voices Augustos story

Patient voices Augustos story

Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Patient voices Eves story

Patient voices Eves story

Eve’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Harold Heart and Dorothy Diabetes

Harold Heart and Dorothy Diabetes

People with type 2 diabetes are up to four times more likely to develop cardiovascular disease than people without diabetes.
Improving Access to Healthcare

Improving Access to Healthcare

According to the UN Sustainable Development Goals, almost half of the global population is not covered by essential health services.
CAROLINA-CARMELINA-Asia-analysis

CAROLINA-CARMELINA-Asia-analysis

CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes